Assess whether a CMO finding is a delay or a refuse-to-file risk (e623f2)

Situation

The desk packet is scientific-advice briefing book after an inspector asking for batch records you cannot produce this week. 505(b)(2) development lead in a labeling team facing a boxed-warning debate has to name A CMO finding is a delay or A refuse-to-file risk for this Pharma & Life Sciences CMC and Development Pathways file.

Decision

505(b)(2) development lead in a labeling team facing a boxed-warning debate must choose A CMO finding is a delay / A refuse-to-file risk using scientific-advice briefing book after an inspector asking for batch records you cannot produce this week.

Hypotheses to test

• An inspector asking for batch records you cannot produce this week is noise around an already-controlled CMC and Development Pathways process in a labeling team facing a boxed-warning debate, given scientific-advice briefing book.
• An inspector asking for batch records you cannot produce this week is the event in scientific-advice briefing book that forces A CMO finding is a delay for 505(b)(2) development lead under Pharma & Life Sciences.
• Scientific-advice briefing book shows a one-file miss after an inspector asking for batch records you cannot produce this week, not a CMC and Development Pathways program failure.
• Scientific-advice briefing book cannot decide a CMO finding is yet after an inspector asking for batch records you cannot produce this week; hold is the only Pharma & Life Sciences close a labeling team facing a boxed-warning debate can defend.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on a CMO finding is.
• Check whether scientific-advice briefing book supports the labeled claim 505(b)(2) development lead would keep.
• Map FDA-response timing and owner in a labeling team facing a boxed-warning debate.
• For this Pharma & Life Sciences CMC and Development Pathways file, read scientific-advice briefing book against an inspector asking for batch records you cannot produce this week and write the one fact that would move a CMO finding is for 505(b)(2) development lead.

Recommendation

Choose A CMO finding is a delay / A refuse-to-file risk on this Pharma & Life Sciences / CMC and Development Pathways packet (scientific-advice briefing book after an inspector asking for batch records you cannot produce this week). Lead with the Pharma & Life Sciences option scientific-advice briefing book can support after an inspector asking for batch records you cannot produce this week, then the two facts that force it, then the Monday action for 505(b)(2) development lead in a labeling team facing a boxed-warning debate.